Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-010"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Variations to the terms of marketing authorisations for medicinal products - Counterfeiting of medicinal products (debate)2
dcterms:Language	"es"^^xsd:language2
lpv:document identification number	"en.20081022.2.3-010"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-0112
lpv:speaker	lp:Cristina Gutiérrez-cortines2
lpv:spokenAs	unknown; Partido Popular (2004-07-20--2009-07-13)3 substitute; Temporary Committee on Climate Change (2007-05-10--2009-02-04)3 member; PETI (2007-02-12--2009-07-13)3 substitute; Delegation for relations with the People's Republic of China (2007-03-14--2009-07-13)3 member; Delegation for relations with Israel (2007-03-14--2009-07-13)3 substitute; CONT (2007-01-31--2009-07-13)3 substitute; Delegation to the EU-Turkey Joint Parliamentary Committee (2004-09-15--2009-07-13)3 substitute; ITRE (2007-01-31--2009-07-13)3 member; EPP-ED (2004-07-20--2009-07-13)3 member; ENVI (2007-01-31--2009-07-13)3
lpv:translated text	"Mr President, on this subject I want to do two things: firstly, congratulate the Commission and Mrs Grossetête, and, secondly, talk about subsidiarity. I have frequently criticised the European Union in this respect, as, for example, with the Services Directive and also the current attack on pharmacies in the name of liberalisation. In these examples, the European Commission has entered into areas which properly come under subsidiarity and which have been developed for each individual society and with which this society is content. In other words, the European Union’s meddling could damage what is working effectively, as in the case of pharmacies. However, in the present case, I feel that this report must be clearly welcomed, bearing in mind that it represents the only way of controlling quality and guaranteeing good health. Why? The reason is that, without a single point of control for all medicinal products, there are too many avenues left open and the system is much more vulnerable to infiltration by harmful or unauthorised products. This is also true in the case of active ingredients on which there was a resolution last year, tabled by Mrs Sartori and myself, which I see has been taken up by the Commission. I therefore feel that this is a good proposal which will cut through a lot of red tape and offer safeguards to society. I also welcome the emphasis placed on information because it is clear that, in a society with patient mobility as it is, where patients can easily travel for treatment and where many elderly people live in countries other than their countries of origin, it is very important that doctors and all health care staff can have access to the same information and criteria in their work."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph